Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside

Advancements in our comprehension of tumor biology and chemoresistance have spurred the development of treatments that precisely target specific molecules within the body. Despite the expanding landscape of therapeutic options, there persists a demand for innovative approaches to address unmet clini...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-08, Vol.16 (17), p.2940
Main Authors: Çakan, Elif, Lara, Olivia D, Szymanowska, Anna, Bayraktar, Emine, Chavez-Reyes, Arturo, Lopez-Berestein, Gabriel, Amero, Paola, Rodriguez-Aguayo, Cristian
Format: Article
Language:English
Subjects:
Acids
Angioplasty
Antisense oligonucleotides
Antisense RNA
Antisense therapy
Cancer
Cancer therapies
Carcinogens
Cell signaling
Chemical modification
Chemoresistance
Clinical trials
Drug delivery
Drug development
Drugs
Gene expression
Grb2 protein
Immune response
Immunosuppressive agents
Medical innovations
Medical research
Monoclonal antibodies
Mutation
Neurological diseases
Oncology
Parasitic diseases
Peptides
Proteins
Reviews
RNA-mediated interference
Toxicity
Tumor necrosis factor-TNF
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advancements in our comprehension of tumor biology and chemoresistance have spurred the development of treatments that precisely target specific molecules within the body. Despite the expanding landscape of therapeutic options, there persists a demand for innovative approaches to address unmet clinical needs. RNA therapeutics have emerged as a promising frontier in this realm, offering novel avenues for intervention such as RNA interference and the utilization of antisense oligonucleotides (ASOs). ASOs represent a versatile class of therapeutics capable of selectively targeting messenger RNAs (mRNAs) and silencing disease-associated proteins, thereby disrupting pathogenic processes at the molecular level. Recent advancements in chemical modification and carrier molecule design have significantly enhanced the stability, biodistribution, and intracellular uptake of ASOs, thereby bolstering their therapeutic potential. While ASO therapy holds promise across various disease domains, including oncology, coronary angioplasty, neurological disorders, viral, and parasitic diseases, our review manuscript focuses specifically on the application of ASOs in targeted cancer therapies. Through a comprehensive examination of the latest research findings and clinical developments, we delve into the intricacies of ASO-based approaches to cancer treatment, shedding light on their mechanisms of action, therapeutic efficacy, and prospects.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16172940